Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 344

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 344
---
,014
        )

        Interest expense

        18,391

        22,010

        53,248

        Interest income

        (30,635
        )

        (36,257
        )

        (16,488
        )

        Income tax expense

        25,535

        15,879

        13,525

        Depreciation and amortization expense

        37,724

        44,397

        41,864

        Stock-based compensation expense

        184,300

        182,514

        233,018

        Gain from sale of Priority Review Voucher

        —

        (102,000
        )

        —

        Impairment of strategic investments

        —

        30,321

        2,575

        Loss on debt extinguishment

        —

        387,329

        125,441

        Segment net income (loss)
         
        $
        235,239

        $
        (535,977
        )
         
        $
        (703,488
        )

        Reconciliation of profit or loss

        Adjustments and reconciling items

        —

        —

        —

        Consolidated net income (loss)
         
        $
        235,239

        $
        (535,977
        )
         
        $
        (703,488
        )
       
       (a) Research and development-other includes professional services, up-front, milestone, and other expenses, pre-clinical expenses and research and other expenses.(b) Selling, general and administrative-other includes professional services and other expenses.(c) Other segment items included in segment net income (loss) include accretion of investment discount, net, change in fair value of derivatives and other, net, as well as the items separately presented and not defined as significant expenses below.Significant expense categories that are regularly provided to the CODM include cost of sales (excluding amortization of in-licensed rights), compensation and other personnel expenses, manufacturing expenses, clinical trial expenses, facility- and technology-related expenses, research and development- other and selling, general and administrative- other. The other expense or income information are other segment items and include separate presentation of interest expense, income tax expense, depreciation and amortization, stock-based compensation, which are included in the measure of segment income (loss) but are not significant segment expenses.Assets provided to the CODM for the single segment are